MS Pharma Partners With Mabxience For Bevacizumab In MENA Region
Follows Agreement With Alvion For Rosuvastatin/Ezetimibe In MENA
• By Akriti Seth
Jordan-based MS Pharma has struck a deal with Insud Pharma subsidiary Mabxience to commercialize its bevacizumab biosimilar in the Middle East and North Africa region. The move comes after Mabxience partnered with Zentiva to commercialize bevacizumab in 21 European countries. Meanwhile, MS Pharma has also partnered with Alvion Pharma for rosuvastatin/ezetimibe in the MENA region.
MS Pharma is ready to commercialize bevacizumab and rosuvastatin/ezetimibe in the Middle East and North Africa region • Source: Alamy
Jordan-based MS Pharma has announced entering into an agreement with mAbxience S.L. to commercialize the firm’s bevacizumab biosimilar in the Middle East and North Africa region.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
